Testing usnoflast for ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests an experimental oral medication called usnoflast for people with ALS. It aims to see if the drug can slow the disease's progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have probable or definite ALS (Lou Gehrig's disease).
- Your first ALS symptoms started within the last 2 years.
- Your ALS Functional Rating Scale (ALSFRS-R) score is 35 or higher.
- Your slow vital capacity (a breathing test) is at least 60% of predicted.
- You can swallow capsules.
- You are either not taking certain ALS medicines like riluzole, sodium phenylbutyrate/taurursodiol (Relyvrio), tofersen, or edaravone, or you have been on a stable dose for at least 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug (FHND1002) for people with ALS to see if it can slow down the disease. It's for people with ALS who are in the early to moderate stages, have good breathing, and have been recently diagnosed.
This study tests an investigational drug called NB-4746 for people with ALS. The goal is to see if it can slow the progression of the disease. It is for people diagnosed within the last couple of years who are still able to eat and breathe on their own.
This study tests an investigational drug called ALT001 in people with amyotrophic lateral sclerosis (ALS), a disease that affects nerve cells controlling muscles. The goal is to see if ALT001 can help slow the progression of the disease. Participants will receive the drug and be monitored for safety and effects.
This trial tests a new medication called FHND1002 in healthy adults aged 18 to 45. The goal is to check its safety, how well the body tolerates it, and how it is processed. It is one of the first tests in humans.
This study tests an experimental drug called AMX0114 for people recently diagnosed with ALS. It is an early-phase trial to see if the drug is safe and how it affects the body.
This trial tests a new drug called kamlanoflast to see if it can slow the progression of ALS. It is for people with a recent diagnosis who are showing signs of active disease, and it may help reduce nerve damage.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.